StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Pifeltro (doravirine by Quarter

Pifeltro (doravirine — HIV-1 NNRTI) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Pifeltro (doravirine: $42M in Q4 2025, up 5.0% from a year earlier.

Latest, Q4 2025
42
Period ended Dec 31, 2025
Change on a year earlier
+5.0%
40 in Q4 2024
History
12 quarters
Since Q1 2023
Sources
2
Documents cited below

Where the Q4 2025 figure comes from

“|| Pifeltro | 42 | 40 | 6 | 26 | 26 | -3 | 17 | 13 | 23”

Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPifeltro (doravirine — HIV-1 NNRTI) — Worldwide sales ($M) ($M)Year on yearSource
Q4 2025Dec 31, 202542+5.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202543+2.4%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2025Jun 30, 202541+5.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2025Mar 31, 202545+7.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2024Dec 31, 202440+21.2%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202442+13.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 202439+2.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 202442+23.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 202333–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202337–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 202338–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 202334–Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗

Breakdown

What makes up pifeltro (doravirine

Cite this data

StockData. (2026). Merck Pifeltro (doravirine ($M), quarterly Q1 2023–Q4 2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-pifeltro

See every metric in the Merck KPI table. Data updated Oct 26, 2026.